In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity ...

Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast cancer diagnoses but accounts for a disproportionately high percentage of breast cancer deaths. What sets this ...

Friends, have you heard of triple-negative breast cancer [TNBC]? It’s a particularly aggressive type of breast cancer that can grow and spread faster than other types of breast cancer and has a higher ...

Triple Negative Breast Cancer (TNBC) is one of the most aggresive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...

Triple-negative breast cancer does not respond to targeted breast cancer treatments, which limits treatment to primarily chemotherapy for now.

Triple-negative breast cancer, or TNBC, is a rare and especially aggressive form of breast cancer that grows and spreads faster than other types. Black and Hispanic individuals are disproportionately ...

Sacituzumab govitecan targets Trop-2 and delivers potent chemo directly to TNBC cells. PARP inhibitors are effective in TNBC patients with BRCA mutations. Immune checkpoint inhibitors benefit patients ...

Triple-negative breast cancer (TNBC) was first described as a distinct disease entity 20 years ago. Since that time, there has been tremendous effort invested in understanding the clinical features ...